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Abstract
The clinical expression of type 1 von Willebrand disease may be modified by co-inheritance
of other mild bleeding diatheses. We previously showed that mutations in the platelet P2Y12
ADP receptor gene (P2RY12) could contribute to the bleeding phenotype in patients with
type 1 von Willebrand disease. Here we investigated whether variations in platelet G pro-
tein-coupled receptor genes other than P2RY12 also contributed to the bleeding phenotype.
Platelet G protein-coupled receptor genes P2RY1, F2R, F2RL3, TBXA2R and PTGIR were
sequenced in 146 index cases with type 1 von Willebrand disease and the potential effects
of identified single nucleotide variations were assessed using in silicomethods and heterol-
ogous expression analysis. Seven heterozygous single nucleotide variations were identified
in 8 index cases. Two single nucleotide variations were detected in F2R; a novel c.-67G>C
transversion which reduced F2R transcriptional activity and a rare c.1063C>T transition pre-
dicting a p.L355F substitution which did not interfere with PAR1 expression or signalling.
Two synonymous single nucleotide variations were identified in F2RL3 (c.402C>G, p.A134
=; c.1029 G>C p.V343 =), both of which introduced less commonly used codons and were
predicted to be deleterious, though neither of them affected PAR4 receptor expression. A
third single nucleotide variation in F2RL3 (c.65 C>A; p.T22N) was co-inherited with a synon-
ymous single nucleotide variation in TBXA2R (c.6680 C>T, p.S218 =). Expression and sig-
nalling of the p.T22N PAR4 variant was similar to wild-type, while the TBXA2R variation
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introduced a cryptic splice site that was predicted to cause premature termination of protein
translation. The enrichment of single nucleotide variations in G protein-coupled receptor
genes among type 1 vonWillebrand disease patients supports the view of type 1 von Will-
ebrand disease as a polygenic disorder.
Introduction
Type 1 von Willebrand disease is a highly heterogeneous bleeding disorder that is characterised
by a partial quantitative deficiency of functionally normal von Willebrand factor (VWF) [1].
Its diagnosis is complicated by the incomplete penetrance of the disease and the wide variabil-
ity in plasma VWF levels which are influenced by environmental (e.g. age, stress, exercise) and
genetic factors (e.g. ABO blood group) [1]. While the pathogenetic mechanisms underlying the
disease remain to be fully resolved, data from molecular epidemiological studies indicate that
mutations in the VWF gene (VWF) are present in approximately 65% of index cases diagnosed
with the disorder [2–4]. The majority of VWF sequence variations predict missense substitu-
tions in VWF and the likelihood of identifying a variation is greater in those patients having
more severe deficiency of the protein (3).
The search for genetic factors that may explain the bleeding tendency in the 35% of patients
with no recognisable VWFmutations has focused mainly on the identification of modifier
genes that have a role in influencing plasma VWF levels. Thus, in addition to the ABO locus
which is an established contributor to variation in plasma VWF levels, genome wide associa-
tion studies have identified several other genes encoding proteins that have roles in trafficking
and clearance which have been shown to influence VWF levels [5,6]. The co-existence of other
mild bleeding diatheses might also modify the expression of the bleeding tendency in patients
diagnosed with type 1 VWD. Given the role of VWF in primary haemostasis, and the clinical
similarities of patients with type 1 VWD and platelet bleeding disorders, the bleeding tendency
in patients with type 1 VWDmay be influenced by variation in the genes encoding the recep-
tors and signalling proteins that mediate platelet adhesion and aggregation. Indeed, we have
previously identified two mutations in the platelet P2Y12 ADP receptor gene (P2RY12) in
patients with type 1 VWD who were recruited through the EuropeanMolecular and Clinical
Markers for the Diagnosis and Management of type 1 von Willebrand Disease (MCMDM-
1VWD) study and showed that they could contribute to the bleeding phenotype in these
patients [7,8].
P2Y12 is one of several GPCRs expressed on the cell surface of platelets which, when acti-
vated, generate stimulatory or inhibitory signals that serve to both amplify and limit platelet
recruitment and aggregation at sites of vessel injury. Platelet activation through GPCRs is
mediated primarily via ADP, which, in addition to P2Y12, elicits its response through the P2Y1
ADP receptor; thromboxane A2 (TxA2), which elicits its response through the thromboxane
receptor TP; and thrombin, which activates platelets through protease-activated receptors-1
and -4 (PAR1 and PAR4) [9]. The receptors P2Y1, TP, PAR1 and PAR4 are coupled via Gq to
phospholipase Cβ2 (PLCβ2), activation of which results in an increase in cytosolic Ca2+ levels,
leading to activation of phospholipase A2 (PLA2) and generation of TxA2 which, when
released, activates additional platelets though TP [9,10]. Interaction of TP with TxA2, and of
PAR1 and PAR4 with thrombin, also leads, via G13, to activation of Rho kinase and the cyto-
skeletal responses resulting in platelet shape change [11]. In contrast to the stimulatory effects
of thrombin, ADP and TxA2, the major endothelium-derived inhibitor of platelet activation,
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prostacyclin (PGI2), mediates its protective effects through the platelet Gs-coupled IP receptor
to stimulate adenylyl cyclase, raising cAMP levels and leading to activation of protein kinase A
(PKA) [12].
In this study, we have investigated the possible contribution of variations in the genes
encoding these five GPCRs, to the bleeding tendency of patients diagnosed with type 1 VWD
and recruited to the MCMDM-1VWD study. Our results reveal enrichment of rare and novel
GPCR gene variations among patients with type 1 VWD, which would support a contribution
to the bleeding phenotype.
Subjects and Methods
Genetic studies
The exonic and flanking intronic sequences of P2RY1, F2R, F2RL3, TBXA2R and PTGIR encod-
ing the GPCRs P2Y1, PAR1, PAR4, TP and IP respectively were amplified from the genomic
DNA of 146 index cases recruited through the MCMDM-1VWD study and sequenced on an
automated ABI 3730 DNA capillary sequencer as described earlier [7]. Where a novel sequence
variation was identified in an index case, this was sought in unrelated control subjects recruited
through the same centre as the index case. The number of control subjects tested varied between
centres though a minimum of 80 subjects were tested in all cases.
The MCMDM-1VWD study was supported by the European Community under the Fifth
Framework Program (QLG1-CT-2000-00387) and recruited a total of 154 families historically
diagnosed as having type 1 VWD by their treatment centre based on International Society on
Thrombosis and Haemostasis-Scientific and Standardization Committee on VWF guidelines.
The study protocol was approved by the ethics review committees at the following participating
centres: South Sheffield Research Ethics Committee (Sheffield, UK); Informe del Comité Ético
de Investigación Clinica de Galicia, Santiago de Compostela (La Coruña, Spain); Comité Con-
sultatif de Protection des Personnes dans la Recherche Biomédicale de Bicêtre, Hôpital Bicêtre
(Paris, France); De Commissie Medische Ethiek, Leids Universitair Medisch Centrum (Leiden,
The Netherlands); Ethik Kommission der Ärztekammer (Hamburg, Germany); Aarhus Uni-
versity Hospital, Skejby (Aarhus, Denmark); Forskningsetikkommittén I Lund/Malmö, Medi-
cinska Fakulteten, Lunds Universitet (Malmö, Sweden); Leicestershire Research Ethics
Committee (Leicester, UK); and South Birmingham Local Research Ethics Committee (Bir-
mingham, UK). In accordance with the Declaration of Helsinki, signed informed consent was
obtained from all individuals at the time of recruitment using consent forms in the individual’s
own language [3].
In silico analysis of GPCR gene variations
The potential effects of non-synonymous substitutions on protein function were predicted
using the online Sorting Intolerant From Tolerant (SIFT; http://sift.bii.a-star.edu.sg/), Poly-
morphism Phenotyping v2 (PolyPhen-2; http://genetics.bwh.harvard.edu/pph2/) and Muta-
tionTaster (http://www.mutationtaster.org/) programs. The potential effects of synonymous
variations on splicing were predicted using Human Splice Finder (HSF; http://www.umd.be/
HSF/), SplicePort (http://spliceport.cbcb.umd.edu/) and Alternative Splice Site Predictor
(ASSP; http://wangcomputing.com/assp/index.html). A multi-species alignment was used to
examine conservation of the 5’ untranslated region (UTR) of the F2R gene using the Ensembl
orthologues alignment tool available at http://www.ensembl.org. The frequencies of usage of
different codons were obtained from the online Graphical Codon Usage Analyser tool (http://
gcua.schoedl.de/).
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F2R reporter gene constructs and luciferase assays
A fragment spanning nucleotides -453 to +50 of the F2R gene was amplified from the DNA of
an index case who was found to be heterozygous for a single nucleotide transition in the F2R
5’UTR (c.-67G>C). The primers were designed to incorporate restriction sites for Xho I and
Hind III at the 5’ and 3’ ends respectively of the amplified product thereby facilitating direc-
tional cloning into pGL3.10[luc2] upstream of the firefly luciferase gene to derive wild type
-67G and variant -67C F2R reporter gene constructs. HEK293T cells [13], maintained in
DMEM supplemented with 10% fetal calf serum (FCS) were seeded at a density of 2x104 cells/
well in 24-well plates and allowed to adhere for 24 hours. Cells were then transfected with 200
ng of either the -67G or -67C F2R luciferase reporter construct, or the empty vector (pGL3.10
[luc2]) and 200 ng of the Renilla luciferase reporter, pRLnull, as a control (Promega, UK) using
Lipofectamine LTX (Life Technologies, UK) according to manufacturers’ instructions. Forty-
eight hours post-transfection, cells were lysed and luciferase activity assessed using the Dual
Luciferase Reporter Assay system (Promega, UK). Luciferase levels were normalised for trans-
fection efficiency using Renilla activity and data analysed using an unpaired t-test, with p val-
ues less than 0.05 being considered significant.
TBXA2Rmini-gene constructs and mini-gene expression analysis
A 1,221 bp fragment corresponding to all of exon 2 and 120 bp of each of the flanking introns
of TBXA2R was synthesised and supplied in the plasmid pBMH (Biomatik, US). The fragment
was removed byHind III digestion and cloned into the pET01 Exontrap cloning vector (MoBi-
Tec, Germany) to derive pET-TBXA2R-WT. The c.654C>T SNV identified in TBXA2R was
then introduced into pET-TBXA2R-WT by site-directed mutagenesis using the Stratagene
QuikChange Site-Directed Mutagenesis Kit according to manufacturers’ instructions, and the
orientation and integrity of the cloned WT and variant TBXA2R sequences confirmed by
sequencing. HEK293 cells were transfected with either the WT or variant TBXA2R exontrap
vectors using Lipofectamine LTX (Life Technologies, UK). Forty eight hours later, the cells
were harvested and RNA isolated using the EZ-RNA Total RNA Isolation Kit (Geneflow, UK).
RNA was transcribed to cDNA using a primer specific for the 3’ exon located in the exontrap
vector, and the cloned TBXA2R fragments and flanking vector sequences were amplified by
PCR using oligonucleotide primers specific for the 5’ and 3’ exons located in the backbone of
the exontrap vector.
PAR1 and PAR4 expression studies
CFP-tagged wild-type (WT) PAR4 and GFP-tagged WT PAR1 expression constructs were gen-
erated as previously described [14] and were a kind gift from Professor R Plevin (University of
Strathclyde). Mutations were introduced using a Stratagene QuikChange Site-Directed Muta-
genesis Kit by polymerase chain reaction amplification. Subsequent products were transformed
into DH5a cells, ampicillin-resistant colonies were amplified and the presence of the mutation
confirmed by sequencing. HEK293 cells were maintained in DMEM supplemented with 10%
FCS, penicillin (100 units/ml) and streptomycin (100 μg/ml). Cells were grown to 50% con-
fluency on coverslips or imaging dishes coated with 0.1mg/mL Poly-D-Lysine (Sigma, UK) and
transfected with PAR1 or PAR4 receptor expression plasmids using JET PEI (Polyplus, UK)
according to manufacturers’ instructions.
Where expression was quantified, transfection efficiency was calculated by counting the
number of DAPI-stained cells that were CFP positive. Mean data was taken from 3 indepen-
dent experiments.
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Western Blotting
Cells were lysed and solubilised in RIPA lysis buffer [50 mM Tris, 10 mM ethylenediaminetet-
raacetic acid (EDTA), 150 mMNaCl, 0.5% deoxycholate, 0.1% SDS, 1% Triton-X-100, pH 7.5)
containing protease inhibitors (Roche). Samples were separated by SDS-PAGE and subjected
to immunoblotting using an anti-GFP antibody (Roche, 1:1000).
Single-Cell Ca2+ Imaging
HEK293 cells were grown on 35 mm glass bottomed Microwell dishes (MatTek, UK) for imag-
ing and transfected with CFP or GFP-tagged WT or mutant PAR receptor DNA. Cells were
washed with HEPES-buffered saline buffer (HBBS; 130 mMNaCl, 3 mM KCl, 10 mMHEPES,
1 mMMgCl2, 2 mM CaCl2 and 30 mMD-glucose, pH 7.3) and loaded with 3μM Fura-2 cal-
cium sensitive dye for 1 hour at 37°C. Cells were washed with HBBS and maintained at room
temperature. Ca2+ imaging was carried out on a Leica DMIRBE inverted widefield microscope.
A single snapshot of cells was captured using a CFP filter prior to live cell imaging to allow
identification of transfected cells. Ratiometric fluorescence imaging was performed under con-
trol of MetaFluor Imaging software (Molecular Devices). A charge-coupled device camera
(CoolSNAP HQ2, Photometrics) was used to collect fluorescence images (emission wave-
length,*515 nm) from a 40× objective. Pair-wise exposures to 340 and 380 nm of excitation
light were provided by a Sutter DG-5 Plus illumination source (Sutter Instrument Company).
Drugs were applied directly to the imaging dish by pipette. All experiments were performed at
room temperature. Changes in single cell intracellular Ca2+ in transfected (GFP or CFP- posi-
tive) and non-transfected (GFP or CFP-negative) cells were measured using the CFP fluores-
cence to identify regions of interest. All data are presented as the change in the 340:380 ratio.
Results
Study design and evaluation of bleeding symptoms
The MCMDM-1VWD study aimed to determine the value of clinical, phenotypic and molecu-
lar markers for the diagnosis of type 1 VWD by undertaking an extensive assessment of the
clinical and laboratory phenotype, and VWF analysis in families diagnosed with type 1 VWD.
In total, 154 index cases historically diagnosed with type 1 VWD were recruited through 14
participating treatment centres in 9 European countries. Cases were recruited to reflect the full
clinical spectrum of type 1 VWD, and therefore included milder cases as well as the more
severe highly penetrant type 1 VWD. In addition to the index cases, between 74 and 105
healthy control subjects from each of the participating treatment centres were recruited to the
study. None of the control subjects had sought medical attention for a bleeding disorder prior
to being enrolled in the study. All subjects provided blood samples for phenotypic and geno-
typic analysis as described previously [3]. In addition, bleeding symptoms were recorded retro-
spectively for all index cases, and a subgroup of the control subjects using a questionnaire to
derive a quantitative measure of bleeding known as the bleeding score, a value greater than 3
being considered abnormal [15].
Identification of single nucleotide variations in GPCR genes
Sequence analysis of P2RY1, F2R, F2RL3, TBXA2R and PTGIR in DNA from 146 of the index
cases recruited to the MCMDM-1VWD study identified seven candidate heterozygous single
nucleotide variations (SNVs) in eight index cases denoted P1 to P8 (Table 1). The bleeding
scores varied widely among these index cases, ranging from a score of 4 in P1 to a score of 20
in P7 (see Table 1). No SNVs were identified in P2RY1. F2R SNVs were detected in 2 index
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cases (P1 and P2); a novel single nucleotide transversion in the 5’UTR (c.-67G>C) was identi-
fied in P1, and a non-synonymous SNV (c.1063C>T) predicting a p.L355F substitution in the
7th transmembrane domain of PAR1 was detected in P2. The c.1063C>T SNV is listed on
dbSNP as rs140912041, and reported to have a minor allele frequency (MAF) of 1.16x10-4 (1/
8600 alleles tested) among European Americans. Novel F2RL3 SNVs were identified in three
index cases (P3 to P5). P3 was heterozygous for a non-synonymous SNV in F2RL3 (c.65C>A)
which predicted a p.T22N substitution in PAR4 and was co-inherited with a synonymous SNV
(c.6680C>T, p.S218 =) in TBXA2R which encodes the thromboxane receptor, TP. Synony-
mous F2RL3 SNVs were identified in P4 and P5 (c.402C>G, p.A134 =; c.1029G>C p.V343 =).
None of these SNVs was present among at least 80 control subjects recruited through the same
centres as the cases. A non-synonymous PTGIR SNV (c.44T>C, p.V15A) was identified in 3
index cases from 2 centres (P6 to P8). This SNV is listed on dbSNP as a rare polymorphism
(rs200213497; MAF 0.002) and also occurred in 2 control subjects (2 alleles of 326 examined)
in this study. Since it was predicted to be benign by three online tools, it was not investigated
any further. Further studies were undertaken to investigate the potential functional conse-
quences of the SNVs identified in F2R and F2RL3.
c.-67G>C in the 5’UTR of F2R alters transcriptional activity
The F2R c.-67G>C transversion identified in P1, occurs in an untranslated region of exon 1 of
F2R. Comparison of the human F2R sequence across this region with the orthologous sequence
from 10 other mammalian species revealed that nucleotide -67 was conserved in all 8 of the
species having orthologous sequence across the region examined, leading us to speculate that
this transversion could influence F2R transcription (Fig 1A). This was assessed by transfection
of HEK293T cells with luciferase reporter constructs containing 5’UTR sequences of F2R (-453
to +50) corresponding to either the -67G (WT) or -67C (variant) allele and determination of
the transcriptional activity of these fragments by luciferase assay. The -67G F2R reporter
Table 1. GPCR gene variations identified in type 1 VWD patients and their predicted effects.
Gene Protein SNV Effect
on
Protein
SIFT PolyPhen
v2
Mutation
Taster
HSF SplicePort ASSP MAF Bleeding
score
F2R PAR1 c.-67 G>C N/A - - - - - - Novel P1: 4
F2R PAR1 c.1063C>T p.L355F Tolerated Probably
damaging
Disease
causing
- - - 1.16 x
10−4
P2: 12
F2RL3 PAR4 c.65C>A* p.T22N Tolerated Possibly
damaging
Polymorphism - - - Novel P3: 17
F2RL3 PAR4 c.402C>G p.A134
=
- - Disease
causing
No
changes
Increased
acceptor &
donor sites
No
changes
0.002 P4: 7
F2RL3 PAR4 c.1029G>C p.V343
=
- - Disease
causing
No
changes
No changes No
changes
Novel P5: 5
TBXA2R TP c.654C>T* p.S218
=
- - Disease
causing
New
donor
site
New donor
site
Increased
donor site
Novel P3: 17
PTGIR IP c.43T>C p.V15A Tolerated Benign Polymorphism Donor
site
broken
No changes No
changes
0.002 P6: 7; P7:
20; P8: 6
SNV = Single nucleotide variation; MAF = Minor Allele Frequency;
* co-inherited SNVs identiﬁed in index case P3.
doi:10.1371/journal.pone.0143913.t001
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construct was shown to have 2.6-fold higher transcriptional activity than the empty vector
indicating a potential contribution from the 5’UTR fragment to F2R transcription (Fig 1B).
More importantly, the mutated -67C F2R construct showed reduced transcriptional activity
when compared to the WT -67G construct (p = 0.017) to approximately 1.6-fold that of the
empty vector, supporting our prediction that the c.-67G>C SNV affects the transcriptional
activity of the F2R 5’UTR (Fig 1B).
p.L355F substitution in PAR1 does not alter PAR1 expression or
signalling
Leucine 355, which is predicted to be substituted by phenylalanine as a result of the
c.1063C>T transition identified in P2, is located in the 7th transmembrane domain of PAR1.
This residue is highly conserved across mammalian species and its substitution by phenylala-
nine was predicted to be “tolerated”, “probably damaging” or “disease causing” by three
online tools used to predict the effects of non-synonymous substitutions on protein function
(Table 1). We examined the potential effects of the p.L355F substitution on PAR1 signalling
Fig 1. c.-67G>C in the 5’UTR of F2R alters transcriptional activity. (A) Alignment of F2R 5’UTR nucleotide sequences across multiple species, highly
conserved nucleotides are highlighted in black. (B) HEK293T cells were transfected with 200 ng of either -67G or -67C F2R luciferase reporter construct, or
an empty vector control. Forty-eight hours post-transfection, cells were lysed and luciferase activity assessed. Luciferase levels were normalised for
transfection efficiency using Renilla activity. Data shown represents three independent experiments with a minimum of 3 technical replicates to calculate
mean fold change ± SE. (*p<0.05).
doi:10.1371/journal.pone.0143913.g001
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capacity in HEK293 cells by expressing GFP-tagged WT and variant L355F PAR1 receptors
(Fig 2). The WT and L355F receptors were expressed at similar levels on the surface of HEK
cells as assessed by immunofluorescence and western blotting, indicating that the mutation did
not disrupt receptor synthesis or trafficking to the membrane (Fig 2A and 2B). Furthermore,
the signalling capacity of the variant L355F receptor, as assessed by its ability to direct mobili-
zation of Ca2+, was similar to the WT receptor in response to the PAR1 agonist TRAP-6 (Fig
2C). Subsequent assessment of platelet function in the patient using a Multiplate analyser
(Roche) revealed normal aggregation to ADP, collagen, TRAP and arachidonic acid suggesting
that the p.L355F substitution does not impact on platelet function (data not shown).
Characterisation of co-inherited F2RL3 and TBXA2R SNVs
The p.T22N substitution predicted by the novel c.65C>A F2RL3 SNV identified in P3 occurs
in the N-terminal exodomain of PAR4, in the region of the receptor that is removed by throm-
bin cleavage to expose the tethered ligand that effects receptor signalling [16]. This substitution
was predicted to be “possibly damaging” by one online prediction tool, and tolerated by two
other tools (Table 1). We investigated whether the substitution could affect trafficking of
PAR4, and thrombin signalling, by expressing CFP-tagged WT and variant T22N PAR4 recep-
tors, which demonstrated that the PAR4 variant was expressed normally on HEK cells and
showed no detectable differences in expression or signalling in response to thrombin compared
to the WT receptor (Fig 3). The synonymous TBXA2R SNV that was also inherited by P3
(c.6680 C>T, p.S218 =) was predicted to be “disease causing” by Mutation Taster, and the
three splicing prediction tools HSF, SplicePort and ASSP, predicted the introduction of a cryp-
tic donor splice site in exon 2 of the TBXA2R RNA. As P3 was unavailable for further investiga-
tion, it was not possible to confirm the predicted effects of the c.6680C>T SNV on TBXA2R
splicing by platelet RNA analysis. We therefore investigated whether the SNV could alter splic-
ing of the TBXA2R RNA by cloning fragments corresponding to either the WT or variant
TBXA2R sequence into the multiple cloning site of an exon trap vector which contained 5’ and
3’ exons separated by a 600 bp intron sequence into which the TBXA2R sequence was cloned.
The WT and variant Exontrap vectors were transfected into HEK293 cells, and the RNA result-
ing from transcription of the vector sequences transcribed to cDNA and then amplified using
primers located either in the exonic sequences flanking the inserted TBXA2R fragment or
within the TBXA2R fragment. Repeated sequence analysis of the DNA products revealed no
consistent differences in the splicing of the WT and variant constructs (n = 4; data not shown).
Synonymous F2RL3 SNVs
The synonymous SNVs affecting codons 134 (c.402C>G; GCC>GCG; Ala) and 343
(c.1029G>C; GTG>GTC; Val) in F2RL3 which were identified in P4 and P5 respectively were
both predicted to be “disease causing” by Mutation Taster. One of the splicing prediction tools
predicted marginal changes in splicing in the case of the c.402C>G variation, which were not
investigated further. Both SNVs resulted in substitutions of codons that were preferentially
used in the human genome by less frequently used codons. In the case of the c.402C>G SNV,
the most commonly used codon for Ala (GCC; 40%) was substituted by the least used codon
(GCG; 11%), while in the case of the c.1029G>C SNV the variation led to substitution of the
most commonly used codon for Val (GTG; 46%) by the next most frequent codon (GTC;
24%). Given the increasingly recognised contribution of codon usage bias to differential expres-
sion of synonymous alleles, we examined whether the c.402C>G and c.1029G>C SNVs
resulted in differential PAR4 gene expression by introducing the SNVs into the CFP-tagged
expression construct and expressing the constructs in HEK293 cells. Both variants were
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expressed at similar levels to the WT PAR4 and there was no difference in the percentage of
CFP-positive cells between those cells transfected with the WT construct and those expressing
the synonymous variants (Fig 4).
Discussion
We have identified seven heterozygous SNVs affecting F2R, F2RL3, TBXA2R and PTGIR in 8
of 146 patients with a historical diagnosis of type 1 VWD who were enrolled in the MCMDM-
1VWD study. Four of the SNVs were previously unreported and were not observed among at
least 80 control subjects (160 alleles) recruited to the study through the same centres as the
patients. The remaining 3 SNVs (c.1063C>T in F2R; C.402C>G in F2RL3; c.43T>C in
PTGIR) were listed on dbSNP as having allele frequencies of 0.002 or less.
To our knowledge, the c.-67G>C SNV identified in P1 is the first F2R variant to be identi-
fied in an individual with a bleeding disorder. The high conservation of the F2R 5’UTR in the
Fig 2. Expression and functional analysis of WT and L355F PAR1 in HEK293 cells.Cells were transfected with WT or L355F GFP-tagged PAR1. (A)
Total GFP receptor expression was evaluated by immunofluorescence (shown in green). Cells were also stained with DAPI (shown in blue) to allow
comparison of transfection efficiency. Images are representative of 3 independent experiments. (B) Total expression was evaluated by SDS-PAGE of whole
cell lysates transfected with WT or L355F GFP-tagged PAR1 and immunoblotting with an anti-GFP antibody. (C) Signalling was assessed by measuring
changes in intracellular calcium concentration in response to the PAR1 peptide, TRAP6. Data represents mean±SEM, n = 3.
doi:10.1371/journal.pone.0143913.g002
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region encompassing nucleotide -67 suggested a possible role for this region in regulating F2R
expression that could be disrupted by the SNV, which we investigated by examining the pro-
moter activity of 5’UTR fragments corresponding to the -67G and -67C alleles in a reporter
gene assay. The WT construct showed an increase in luciferase activity, when compared to the
empty vector, suggesting a role for the 5’UTR in regulating F2R expression, and the reduction
in luciferase activity that was observed with the -67C construct suggests that the -67G>C SNV
alters transcription factor binding in the 5’UTR. Further investigation will be required to deter-
mine the identity of the transcription factor(s) that bind to the 5’UTR to regulate F2R expres-
sion and mediate the differential transcription caused by the -67G>C transversion. Analysis
of the sequence in the region of nucleotide -67 led us to postulate that the glucocorticoid recep-
tor might transactivate the F2R gene by binding to a glucocorticoid response element in the
Fig 3. Expression and functional analysis of WT and T22N PAR4 in HEK293 cells. Cells were transfected with WT or T22N CFP-tagged PAR4. (A) Total
CFP receptor expression was evaluated by immunofluorescence (shown in blue). Images are representative of 3 independent experiments. (C) Signalling
was assessed by measuring changes in intracellular calcium concentration in response to the PAR4 peptide, AYPGKG. Data represents mean±SEM, n = 3.
doi:10.1371/journal.pone.0143913.g003
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region. However, preliminary experiments not reported here in which we co-expressed the -67
reporter plasmids in the presence of glucocorticoid receptor and dexamethasone allowed us to
rule out this possibility. Platelet PAR1 receptor levels have previously been shown to be stable
over time and to vary 2 to 4-fold between individuals [17,18]. Differences in levels have been
reported to be due at least partly to an intronic polymorphism located upstream of exon 2
(rs168753), which also governs platelet response to the PAR1 specific peptide agonist SFLLRN
[17]. It is possible that, in the presence of other genetic variations (such as the VWFmutation,
blood group O), a reduction in F2R transcription could also contribute to the bleeding ten-
dency. Indeed, differential expression of F2R as a result of polymorphic variation could, in
Fig 4. Expression of WT, c.402 and c.1029 PAR4 in HEK293 cells.Cells were transfected with WT or mutant CFP-tagged PAR4. (A) Total CFP receptor
expression was evaluated by immunofluorescence (shown in pale blue). Cells were also stained with DAPI (shown in dark blue) to allow comparison of
transfection efficiency. Images are representative of 3 independent experiments. (B) Transfection efficiency was quantified by calculating percentage of
DAPI-stained cells that were CFP positive. Data represents mean±SEM, n = 3.
doi:10.1371/journal.pone.0143913.g004
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principle, contribute to the variable heritability of type 1 VWD, and may also contribute to the
increased risk of bleeding associated with the PAR1 antagonists [19].
The heterozygous p.L355F substitution that was identified in P2 occurred in the 7th trans-
membrane domain of PAR1, a region encompassing amino acids alanine 349 to tyrosine 371.
Crystallographic analysis of this region of the receptor has shown it to be involved in binding
to the PAR1 antagonist vorapaxar, which binds to PAR1 to inhibit receptor activation by its
tethered ligand [20]. In particular, tyrosine 353 located in this domain hydrogen bonds with
tyrosine 183 in the 3rd transmembrane domain to form the base of a binding pocket for vora-
paxar. It also forms a hydrogen bond with histidine 255 in the second extracellular loop
(ECL2) which contributes to ECL2 having a closed conformation over the ligand-binding
pocket. Substitution of tyrosine 353 by alanine was found to lead to a reduction in cell surface
expression of the receptor and an associated reduction in agonist peptide activation [20]. In
contrast, we showed that substitution of leucine 355 by phenylalanine did not affect expression
of PAR1 or its ability to direct calcium mobilization. The p.L355F substitution is listed on
dbSNP and population frequency data record it as being present on 1 of 8600 European Ameri-
can and 1 of 4406 African American alleles, suggesting that it may be a rare sequence variant.
Similarly, substitution of the adjacent leucine residue by phenylalanine (p.L354F) has also been
detected on 1 of 4406 African American alleles, which suggests that substitutions at these posi-
tions by nonpolar residues may be tolerated in the receptor, and indeed platelet function as
assessed in P1 would appear to support this, though we cannot exclude the possibility that
these substitutions have subtle effects on platelet function that may, in combination with other
predisposing factors such as a VWF gene defect and blood group O, contribute to a bleeding
tendency.
We identified three SNVs in F2RL3 encoding PAR4, two of which were synonymous
changes in the codons for alanine 134 and valine 343 and predicted to be deleterious. Both
changes caused alterations from preferentially used to rare codons, leading us to hypothesise
that the SNVs could alter the rate of translation or co-translational folding of PAR4 leading to
a reduction in expression of the receptor. Similar mechanisms have been proposed to explain
changes in substrate specificity in theMDR1 gene as a result of a synonymous polymorphism,
and a case of haemophilia B in which the only underlying genetic defect that could be identified
was a synonymous mutation [21,22]. However, in vitro expression of PAR4 constructs bearing
the synonymous variations revealed no difference in the levels of expression when compared to
the WT constructs, suggesting normal translation and folding of the receptor.
The third, non-synonymous, SNV identified in F2RL3 predicted a p.T22N substitution in
PAR4 and was co-inherited with a synonymous TBXA2R SNV that was predicted to alter splic-
ing of the TBXA2R RNA. The former was predicted to be tolerated and indeed no difference in
expression or signalling capacity of the T22N PAR4 variant was observed compared to the WT
receptor after expression in HEK cells. In contrast, the synonymous TBXA2R variant was pre-
dicted to introduce a new donor splice site which if used, would reduce the length of exon 2 by
134 bp. Splicing of the shorter exon 2 to exon 3, would result in a frameshift and introduction
of a premature stop codon 117 codons downstream of codon 218. Unfortunately, as the patient
was unavailable for further study, we were unable to confirm this prediction by examination of
platelet RNA and instead we investigated whether the c.654C>T TBXA2R SNV affected RNA
splicing by expressing mini-gene constructs corresponding to the WT and variant alleles of the
SNV. The results of these experiments supported the predictions that the variant allele caused
differential RNA splicing. However, we have not pursued this approach as the findings were
not consistent or reproducible between experiments. Furthermore, while this approach can be
helpful in providing some indication as to whether a genetic variation causes differential splic-
ing, the results of the analysis may not accurately reflect in vivo splicing of the TBXA2R RNA.
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If the mutation does affect RNA splicing we would predict a partial reduction in surface expres-
sion of the thromboxane receptor on platelets and compromised signalling, which could con-
tribute to the bleeding tendency in the patient. To date, five TBXA2R defects have been
described, four predicting amino acid substitutions (p.R60L, p. D304N, p.W29C, p.N42S) and
a fifth frameshift defect caused by a single nucleotide insertion (c.167dupG) [23–27]. All five
defects have been found to cause platelet dysfunction when tested ex vivo, and all were identi-
fied in subjects with mild mucocutaneous bleeding symptoms who were heterozygous for the
defects. However, in all cases, asymptomatic relatives who were heterozygous for the same
defects were also identified, an observation that has led our group, and others, to conclude that
heterozygosity for TBXA2R defects may not be sufficient to cause abnormal mucocutaneous
bleeding symptoms and indeed it is more likely to be expressed phenotypically when combined
with an additional haemostatic defect such as type 1 VWD.
A shortcoming of this study was the lack of availability of index cases for follow up ex vivo
assessment of platelet function including RNA and flow cytometric analysis, since this would
have allowed confirmation of the in silico predictions of the effects of SNVs identified in the
GPCR genes directly in the patients. We therefore explored the potential effects of the GPCR
SNVs identified in the study using heterologous expression systems. These studies provided
evidence supporting a functional effect for the c.-67G>C SNV in F2R which was found to be
associated with differential F2R promoter activity in a luciferase reporter assay, though whether
this variant is of any significance in vivo remains to be seen. In the case of the c.654C>T SNV
in TBXA2R, while the in silico analysis predicted that this would lead to aberrant splicing of the
TBXA2R RNA, the absence of further samples from the patient precluded platelet RNA analy-
sis to confirm this. On the other hand, heterologous expression studies revealed that the p.
L355F PAR1 and p.T22N PAR4 variants, and the two synonymous PAR4 variants (p.
A134 = and p.V343 =) all behaved similarly to the counterpart wild-type receptors. Our find-
ings suggest that these variants are therefore unlikely to be of any significance in vivo, though
we cannot rule out the possibility that they may have subtle effects on receptor expression or
function which are not easily detected after overexpression in heterologous cells. Examination
of the bleeding scores in the eight index cases with GPCR gene SNVs revealed significant bleed-
ing in all cases, and scores that varied widely from 4 to 20. The bleeding scores in the index
cases reflect the experience of bleeding symptoms at the time of historical diagnosis, and
increase with age, and the number of haemostatic challenges faced [15]. Given these factors,
and that most of the SNVs were identified in single cases, the extent to which any given GPCR
SNV contributed to the bleeding tendency could not be determined. Importantly, the lack of
correlation between the predicted effects of SNVs made using the bioinformatic tools and the
findings of the in vitro expression studies, emphasise the importance of using several computa-
tional tools to predict the potential effects of candidate gene variants, and of confirming the
predictions where possible in appropriate experimental systems [28].
If we include the two P2RY12 SNVs previously identified in the MCMDM-1VWD cohort,
10 of the 146 index cases studied are heterozygous for GPCR gene SNVs (6.8.%). The enrich-
ment of novel or rare SNVs in GPCR genes mediating platelet aggregation among type 1 VWD
patients, and the absence of the same variants from control subjects supports a contribution
from loci other than VWF to the bleeding phenotype of patients with type 1 VWD, which is
consistent with the view of mild type 1 VWD as a polygenic disorder. We anticipate that the
application of next generation sequencing technologies to the genetic investigation of patients
with type 1 VWD and platelet bleeding disorders will reveal additional cases of these and
indeed other rare GPCR variants, which will ultimately allow assessment of their contribution
to the bleeding tendency in affected patients.
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